Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ioxitalamic acid is an ionic, high-osmolar iodinated contrast medium (HOCM) used primarily for medical imaging of the gastrointestinal tract. As a first-generation ionic monomer, it functions as a radiopaque agent that absorbs X-rays, thereby enhancing the visualization of internal structures during X-ray and computed tomography (CT) procedures. It is typically administered orally or rectally as sodium or meglumine salts (e.g., under the brand name Telebrix) to opacify the bowel, facilitating the differentiation of bowel loops from adjacent soft tissue masses. Due to its high osmolarity (1500-1800 mOsm/kg) and potential for significant side effects, its use is generally restricted to cases where barium sulfate is contraindicated, and it is not intended for intravascular administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ioxitalamic acid.